Background: Vasopressor medications raise blood pressure through vasoconstriction and are essential in reversing the hypotension seen in many critically ill patients. Previously, vasopressor administration was largely limited to continuous infusions through central venous access.
Objectives Of The Review: This review addresses the clinical use of vasopressors in various shock states, including practical considerations and innovations in vasopressor administration. The focus is on the clinical administration of vasopressors across a range of shock states, including hypovolemic, distributive, cardiogenic, and obstructive shock.
Discussion: Criteria for starting vasopressors are not clearly defined, though early use may be beneficial. A number of physiologic factors affect the body's response to vasopressors, such as acidosis and adrenal insufficiency. Peripheral and push-dose administration of vasopressors are becoming more common. Distributive shock is characterized by inappropriate vasodilation and vasopressors play a crucial role in maintaining adequate blood pressure. The use of vasopressors is more controversial in hypovolemic shock, as the preferred treatment is correction of the volume deficit. Evidence for vasopressors is limited in cardiogenic shock. For obstructive shock, vasopressors can temporize a patient's blood pressure until definitive therapy can reverse the underlying cause.
Conclusion: Across the categories of shock states, norepinephrine has wide applicability and is a reasonable first-line agent for shock of uncertain etiology. Keeping a broad differential when hypotension is refractory to vasopressors may help to identify adjunctive treatments in physiologic states that impair vasopressor effectiveness. Peripheral administration of vasopressors is safe and facilitates early administration, which may help to improve outcomes in some shock states.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jemermed.2024.03.004 | DOI Listing |
Mol Biol Rep
January 2025
Department of Internal Medicine, School of Medicine, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran.
Dengue virus (DENV) poses a considerable threat to public health on a global scale, since about two-thirds of the world's population is currently at risk of contracting this arbovirus. Being transmitted by mosquitoes, this virus is associated with a range of illnesses and a small percentage of infected individuals might suffer from severe vascular leakage. This leakage leads to hypovolemic shock syndrome, generally known as dengue shock syndrome, organ failure, and bleeding complications.
View Article and Find Full Text PDFDeath Stud
January 2025
IDEES Multidisciplinary Research Group, Faculty of Arts and Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon.
On August 4, 2020, an explosion in the Beirut Port in Lebanon caused over 220 deaths and 76,000 injuries. The blast, which is considered a national tragedy, had profound impacts on Lebanese citizens, notably the traumatic loss for families who lost a loved one. This qualitative study explored the experiences of loss and adaptation among bereaved families following the Beirut Port explosion from a psychosocial perspective.
View Article and Find Full Text PDFCureus
December 2024
Internal Medicine, Dow University of Health Sciences, Civil Hospital Karachi, Karachi, PAK.
Malaria is highly prevalent in West and Central Africa. In the United States, most reported cases are due to immigration from endemic regions. Severe malaria caused by Plasmodium ovale is rare.
View Article and Find Full Text PDFEClinicalMedicine
January 2025
University of Paris Cité, Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), Paris, France.
Background: Cardiogenic shock (CS) is a heterogeneous clinical syndrome, making it challenging to predict patient trajectory and response to treatment. This study aims to identify biological/molecular CS subphenotypes, evaluate their association with outcome, and explore their impact on heterogeneity of treatment effect (ShockCO-OP, NCT06376318).
Methods: We used unsupervised clustering to integrate plasma biomarker data from two prospective cohorts of CS patients: CardShock (N = 205 [2010-2012, NCT01374867]) and the French and European Outcome reGistry in Intensive Care Units (FROG-ICU) (N = 228 [2011-2013, NCT01367093]) to determine the optimal number of classes.
Int J Cardiol Heart Vasc
February 2025
Department of Anesthesiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Background: Levosimendan (LEVO), a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, has been widely used for decades in medical and surgical patients for advanced heart failure (HF), right ventricular failure, cardiogenic shock, takotsubo cardiomyopathy, pulmonary hypertension, and so on. Currently, as the limited scope and lack of comprehensive data in current LEVO publications, there is an increasing obstacle to conducting new studies that require integrated information and quantifiable results. Thus, the current study was performed to identify the research trends and hot spots in LEVO-related publications using bibliometric software.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!